IP Library › Granted Patent US 12,370,193
Granted Patent B2
US 12,370,193 · App. 17/491,834 · Granted Jul 29, 2025

Method of inhibiting TREM-1

Inventors: Patrick R. Griffin (Jupiter, FL); Mi Ra Chang (Jupiter, FL); Jason Fisherman (Brookline, MA); Peter Suzman (Newton, MA)
Assignee: University of Florida Research Foundation, Incorporated
A61K31/506A61P3/04A61P29/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,370,193
App. No.
17/491,834
Granted
Jul 29, 2025
Kind
B2
Abstract

Disclosed herein are methods and uses of the polypharmacological modulator SR1903 and related compounds for inhibiting triggering receptor expressed on myeloid cells-1 (TREM-1) and treating diseases and conditions that are related to or mediated by TREM-1, such as inflammatory diseases, autoimmune diseases, metabolic disorders, and castration resistant prostate cancer (CRPC).

Claims (11)

1. A method of treating an inflammatory disease or autoimmune disease and protecting against loss of thymocytes in a subject in need thereof,

wherein the inflammatory disease or autoimmune disease is selected from the group consisting of inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, gout, lupus-associated arthritis, psoriasis, psoriatic arthritis, multiple sclerosis, and chronic inflammatory demyelinating polyneuropathy,

the method comprising administering to said subject an effective amount of the compound SR1903:

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the inflammatory disease or autoimmune disease is selected from the group consisting of rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, gout, and lupus-associated arthritis.

3. The method of claim 1 , wherein the inflammatory disease or autoimmune disease is IBD.

4. The method of claim 3 , wherein the IBD is IBD refractory to anti-TNF therapy.

5. The method according to claim 1 , wherein the protection against loss of thymocytes is determined by measuring the T-cell count of the subject before the administration of the SR1903 and measuring the T-cell count after the administration of the SR1903, whereby the T-cell counts of the subject are within about 10% of each other.

6. The method of claim 1 , wherein the inflammatory disease or autoimmune disease is psoriasis or psoriatic arthritis.

7. The method of claim 1 , wherein the inflammatory disease or autoimmune disease is multiple sclerosis or chronic inflammatory demyelinating polyneuropathy.

8. The method of claim 1 , wherein the inflammatory disease or autoimmune disease is selected from the group consisting of ankylosing spondylitis, juvenile idiopathic arthritis, gout, and lupus-associated arthritis.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2022
From: THE SCRIPPS RESEARCH INSTITUTE
To: UNIVERSITY OF FLORIDA BOARD OF TRUSTEES
Reel/Frame 060008/0861 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2022
From: UNIVERSITY OF FLORIDA BOARD OF TRUSTEES
To: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
Reel/Frame 060008/0881 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2022
From: GRIFFIN, PATRICK R.; CHANG, MI RA; FISHERMAN, JASON; SUZMAN, PETER
To: THE SCRIPPS RESEARCH INSTITUTE
Reel/Frame 058747/0140 →
Continuity (4)
Continuation PCTUS2020026526 · Apr 3, 2020
Provisional Application 62828805 · Apr 3, 2019
Provisional Application 62828978 · Apr 3, 2019
Related Publication 20220117965A1 · Apr 21, 2022
References Cited (36)
US 9586928B2 · Kamenecka et al. · 2017 [cited by applicant]
US 20080247955A1 · Kuai et al. · 2008 [cited by applicant]
US 20180085348A1 · Chen et al. · 2018 [cited by applicant]
WO WO2012158784A2 · 2012 [cited by applicant]
WO 2017007712A1 · 2017 [cited by applicant]
“TREM-1 Pathway Activation in COVID-19 (CoviTrem1),” ClinicalTrials.gov Identifier: NCT04544891 (2020). [cited by applicant]
Amrun, S. et al., “TREM-1 Activation is a Potential Key Regulator in Driving Severe Pathogenesis of Enterovirus A71 Infection”, Scientific Reports, 10:3810 | https://doi.org/10.1038/s41598-020-60761-5 (2020). [cited by applicant]
Brocklebank, V. et al., “Thrombotic Microangiopathy and the Kidney”, Clin. J. Am. Soc. Nephrol., vol. 13, Feb. 2018, 300-317. [cited by applicant]
Campbell, G. et al., “TREM-1 Protects HIV-1-Infected Macrophages from Apoptosis Through Maintenance of Mitochondrial Function”, Amer. Soc. Microbio., vol. 10, Iss. 6: 1-17 (2019). Downloaded from https://journals.asm.or… [cited by applicant]
Chang, M. et al., “Pharmacological Repression of RORy is Therapeutic in the Collagen-Induced Arthritis Experimental Model”, Arthritis Rheumatol., vol. 66, No. 3: 579-588 (2014). [cited by applicant]
Chang, M. R. et al., “Unique Polypharmacology Nuclear Receptor Modulator Blocks Inflammatory Signaling Pathways”, ACS Chemical Biology, vol. 14: 1051-1062 (2019). [cited by applicant]
Channappanavar, R. et al., “Pathogenic Human Coronavirus Infections: Causes and Consequences of Cytokine Storm and Immunopathology”, Seminars in ImmunoPathology, vol. 39 :529-539 (2017). [cited by applicant]
Cioni, B. et al., “Androgen Receptor Signalling in Macrophages Promotes TREM-1-Mediated Prostate Cancer Cell Line Migration and Invasion”, Nature Communications, 11:4498 (2020), p. 1-17. https://doi.org/10.1038/s41467-0… [cited by applicant]
De Stoppelaar, S. F. “Platelets: Versatile Effector Cells in Pneumonia and Sepsis”, 's-Hertogenbosch: Uitgeverij BOXPress, UVA-DARE (Digital Academic Repository) University of Amsterdam, 183-192 (2015). [cited by applicant]
Edel, Y. et al., “Elevated Plasma Level of Soluble Triggering Receptor Expressed on Myeloid Cells-1 is Associated with Inflammation Activity and is a Potential Biomarker of Thrombosis in Primary Antiphospholipid Syndrom… [cited by applicant]
Gao, S. et al., “The Characteristics and Pivotal Roles of Triggering Receptor Expressed on Myeloid Cells-1 in Autoimmune Diseases”, Autoimmunity Reviews, vol. 18, 2019, 25-35. [cited by applicant]
Hoang, T. et al., “Global Gene Expression profiling Identifies new Therapeutic Targets in Acute Kawasaki Disease”, Genome Medicine, vol. 6, No. 102: 1-13 (2014). [cited by applicant]
Hotez, P. et al., “COVID-19 Vaccine Design: The Janus Face of Immune Enhancement”, Nature Reviews | Immunology, https://doi.org/10.1038/ S41577-020-0323-4, 2020. [cited by applicant]
Joffre, J. et al., “Genetic and Pharmacological Inhibition of TREM-1 Limits the Development of Experimental Atherosclerosis”, J. Am. Coll. Cardiology, vol. 68, No. 25, 2776-2793 (2016). [cited by applicant]
Jolly, L. et al., “Triggering Receptor Expressed on Myeloid Cells-1: A New Player in Platelet Aggregation”, Thrombosis and Haemostasis, 117: 1772-1781 (2017). [cited by applicant]
Liu, T. et al., “Blocking Triggering Receptor Expressed on Myeloid Cells-1 Attenuates Lipopolysaccharide-Induced Acute Lung Injury via Inhibiting NLRP3 Inflammasome Activation”, Scientific Reports, 6:39473 | DOI: 10.103… [cited by applicant]
Marik, P. et al., “SIRS, qSOFA and New Sepsis Definition”, J. Thorac. Dis., vol. 9, No. 4: 943-945 (2017). [cited by applicant]
Merrill, S. et al., “Complement-Driven Anemia: More Than Just Paroxysmal Nocturnal Hemoglobinuria”, Hematology, 371-376 (2018). [cited by applicant]
Mohamadzadeh, M. et al., “Activation of Triggering Receptor Expressed on Myeloid Cells-1 on Human Neutrophils by Marburg and Ebola Viruses”, J. Virol., vol. 80, No. 14, 2006, 7235-7244. [cited by applicant]
Moore, J. et al., “Cytokine Release Syndrome in Severe COVID-19”, Science, 10.1126/science.abb8925 (2020), Apr. 17, 2020, 1-4. [cited by applicant]
Page, M. et al., “A Champion of Host Defense: A Generic Large-Scale Cause for Platelet Dysfunction and Depletion in Infection”, Seminars in Thrombosis & Hemostasis, vol. 46, No. 3, (2020) 302-319. [cited by applicant]
Rivas, M. et al., “Kawasaki Disease: Pathophysiology and Insights from Mouse Models”, Nature Reviews | Rheumatology, vol. 16, Jul. 2020, 391-405. [cited by applicant]
Roe, K. et al., “Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1): A New Player in Antiviral Immunity?”, Frontiers in Microbio., vol. 5, Art. 627, Nov. 26, 2014, 1-11. [cited by applicant]
Schultz, D. et al., “Carrageenan Containing Over-the-Counter Nasal and Oral Sprays Inhibit SARS-CoV-2 Infection of Epithelial Cultures”, Downloaded from journals.physiology.org/journal/ajplung (073.119.016.060) on Mar. … [cited by applicant]
Solaimanzadeh, I. “Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19)”, Cureus 12(3): e7343,… [cited by applicant]
Tammaro, A. et al., “TREM-1 and its Potential Ligands in Non-Infectious Diseases: From Biology to Clinical Perspectives”, Pharmac. & Therapeutics, vol. 177, 2017, 81-95. [cited by applicant]
Tang, X. et al., “Comparison of Hospitalized Patients with ARDS Caused by COVID-19 and H1N1”, Chest, vol. 158, No. 1, 2020, 195-205. [cited by applicant]
Yeh, A. et al., “Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy: Current Paradigm and Novel Therapies”, Bone Marrow Transplantation, 2017, 1-9. [cited by applicant]
Zuo, Y. et al., “Neutrophil Extracellular Traps in COVID-19”, JCI Insight, https://doi.org/10.1172/jci.insight.138999, 2020. [cited by applicant]
Extended European Search Report for EP App. No. 20784271.7 mailed Apr. 25, 2023. [cited by applicant]
Guntermann et al., Retinoic-acid-orphan-receptor-C inhibition suppresses Th17 cells and induces thymic aberrations. JCI Insight. Mar. 9, 2017;2(5):e91127. doi: 10.1172/jci.insight.91127. 16 pages. [cited by applicant]